Login / Signup
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy.
Efrat Luttwak
Mitchell R Smith
Andrew D Zelenetz
Published in:
Expert opinion on pharmacotherapy (2023)
Keyphrases
</>
protein kinase
diffuse large b cell lymphoma
small molecule
replacement therapy